Soligenix appoints Timothy Coté to board, expands size to six

SOLIGENIX, INC.

Board expanded from 5 to 6; Timothy R. Coté, M.D. appointed as director, term expiring at 2023 annual meeting.
Dr. Coté granted fully-vested non-qualified stock option for 15,000 shares at $1.42 per share, plus $35,000 annual cash.
Former FDA OOPD director, implementing Orphan Drug Act; founded Coté Orphan sold to IQVIA for $20M.
Also CEO of Silk Road Therapeutics; Soligenix recently acquired exclusive option to its PTX topical for Behçet's Disease.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Timothy R. Coté

director

SNGX · SOLIGENIX, INC.

Effective: 2023-05-03
Filed: May 3, 2023, 7:59 PM ET

On May 3, 2023, the Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) increased the size of the Board from five to six members and appointed Timothy R. Coté, MD, MPH as a director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy R. Coté was appointed as director at SOLIGENIX, INC..

Action: appointed
Role: director

Exact text from the filing

On May 3, 2023, the Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) increased the size of the Board from five to six members and appointed Timothy R. Coté, MD, MPH as a director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders.

View on SEC.gov

SOLIGENIX, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-007875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.